Psychotic Disorders Clinical Trial
— FACTOfficial title:
Forensic Assertive Community Treatment: An Emerging Model of Service Delivery
| Verified date | February 2017 |
| Source | University of Rochester |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The FACT model (ACT + legal leverage in the form of judicial monitoring) will be compared to
enhanced outpatient treatment (close outpatient follow-up without judicial monitoring).
Seventy adults with psychotic disorders in Monroe County who are convicted of a misdemeanor
will be randomly assigned to each treatment group and followed for 12 months. Primary
outcomes will include criminal justice and mental health service utilization rates,
treatment adherence, psychiatric symptoms, substance abuse, homelessness, perceived
coercion, and consumer satisfaction. Service utilization outcomes will be tracked using
established mental health and criminal justice databases.
Hypotheses are:
1. FACT (ACT plus judicial monitoring) will have a greater effect than enhanced TAU in
promoting treatment adherence among high-risk adults with psychotic disorders.
2. FACT (ACT plus judicial monitoring) will have a greater effect than enhanced TAU in
preventing arrest, incarceration, emergency department and inpatient hospital use among
high-risk adults with psychotic disorders.
| Status | Completed |
| Enrollment | 53 |
| Est. completion date | May 2014 |
| Est. primary completion date | May 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Individuals diagnosed with any psychotic disorder such as Schizophrenia, Schizoaffective Disorder, Bipolar Disorder with Psychotic Features, Depressive Disorder with Psychotic Features, and Psychotic Disorder, Not Otherwise Specified. - Individuals currently facing misdemeanor or violation charges who have not yet been sentenced. Exclusion Criteria: - Individuals do not have or cannot be diagnosed with a psychotic disorder. - Individuals currently facing felony charges - Individuals currently involved in any type of legal leverage including probation, parole, drug or mental health court supervision, Assisted Outpatient Treatment, or Criminal Procedure Law status. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Monroe County Jail | Rochester | New York |
| Lead Sponsor | Collaborator |
|---|---|
| University of Rochester | National Institute of Mental Health (NIMH) |
United States,
Lamberti JS, Deem A, Weisman RL, LaDuke C. The role of probation in forensic assertive community treatment. Psychiatr Serv. 2011 Apr;62(4):418-21. doi: 10.1176/ps.62.4.pss6204_0418. — View Citation
Lamberti, J., & Weisman, R. (2010). Forensic assertive community treatment: Origins, current practice, and future directions. In H. Dlugacz (Ed.), Reentry Planning for Offenders With Mental Disorders (1 ed., Vol. 1, pp. 145-169). Kingston, NJ: Civic Research Institute.
Lamberti, JS. (2011). Legal Leverage in the Treatment of Adults With Severe Mental Illness, in Workplace Violence in Mental Health and General Health Care Settings. Pages 225 - 236. M. Privitera, editor. Jones and Bartlett, Pages 225-236.
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Jail Recidivism | The study will measure number of arrests, number of incarcerations, and total number of jail and/or prison days in the time frame described above. | For the one year subjects are in the study. | |
| Primary | Mental Health Service Utilization | The study will measure number of hospitalizations, number of hospital days, number of emergency room visits, number of outpatient mental health visits as primary outcome measures, and treatment appointment adherence. | For the one year subjects are in the study. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
| Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
| Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
| Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
| Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
| Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
| Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
| Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
| Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
| Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
| Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
| Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
| Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
| Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
| Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
| Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
| Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
| Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
| Completed |
NCT00226278 -
Safety Study of ORG 34517 for Major Depression With Psychotic Features
|
Phase 2 |